Assessing Presenting Symptoms, Co-Morbidities, and Risk Factors for Mortality in Underserved Patients With Non-Hereditary Early-Onset Colorectal Cancer.
clinical symptoms
co-morbid conditions
early-onset colorectal cancer
rectal bleeding
risk factors
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
accepted:
21
06
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Background The presenting symptoms and co-morbidities contributing to mortality in young patients (age < 50 years old) with colorectal cancer (CRC) are poorly understood. We reviewed these features in our patient population with non-hereditary early-onset CRC (EO-CRC). Study aim This study aimed to assess characteristics of patients with a diagnosis of non-hereditary EO-CRC, including presenting symptoms and metabolic disorders contributing to mortality in underserved areas of southwest Virginia. Methods In this retrospective observational study, we selected patients aged 18-50 years with a diagnosis of non-hereditary EO-CRC from 2008 to 2016 at Carilion Roanoke Memorial Hospital. The electronic medical record was queried to identify demographic data, medical history, histopathology results, lab values, and mortality. The cumulative risks of symptoms and co-morbid metabolic disorders was estimated using Kaplan-Meier curves. Results We identified 139 patients with non-hereditary EO-CRC (mean age 41.6 ± 6.9 years). Almost half of these patients were obese (BMI > 30), 30.9% had a diagnosis of hypertension, 29% had hyperlipidemia (HLD), and 17.35% had diabetes mellitus type 2 (DM2). Diagnosis was delayed by 4.5 months from initial presentation, and 17% had advanced disease (stage III/IV). Also, 68.5% of patients were symptomatic with one to three symptoms, most commonly with rectal bleeding (45.3%). The chronicity of HLD (≥5 years) was associated with reduced survival in our patients with EO-CRC. The survival of females with multiple metabolic disorders was reduced compared to females with a single metabolic disorder. Conclusions Multiple symptoms, chronic HLD, and female gender with multiple metabolic disorders were factors associated with poor outcomes in non-hereditary EO-CRC patients.
Identifiants
pubmed: 34350080
doi: 10.7759/cureus.16117
pmc: PMC8325966
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16117Informations de copyright
Copyright © 2021, Reddy et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Gastroenterology Res. 2020 Apr;13(2):66-72
pubmed: 32362965
Gastrointest Endosc. 2017 Jul;86(1):18-33
pubmed: 28600070
MMWR Morb Mortal Wkly Rep. 2005 Oct 7;54(39):991-4
pubmed: 16208312
Clin Gastroenterol Hepatol. 2017 May;15(5):728-737.e3
pubmed: 27856366
Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2391-7
pubmed: 17164361
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
J Am Board Fam Med. 2014 Jan-Feb;27(1):42-55
pubmed: 24390885
PLoS One. 2013;8(1):e54242
pubmed: 23372693
Intest Res. 2017 Apr;15(2):203-207
pubmed: 28522950
JAMA Oncol. 2019 Jan 1;5(1):37-44
pubmed: 30326010
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):250-8
pubmed: 26819264
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Cancer. 2004 Dec 15;101(12):2851-8
pubmed: 15526322
J Gastrointest Oncol. 2020 Feb;11(1):121-126
pubmed: 32175114
Gastroenterology. 2020 Jan;158(2):341-353
pubmed: 31394082
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Medicine (Baltimore). 2008 Sep;87(5):259-263
pubmed: 18794708
World J Gastroenterol. 2016 Apr 7;22(13):3611-20
pubmed: 27053853
J Hum Hypertens. 2005 May;19(5):373-9
pubmed: 15703772
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947
Integr Blood Press Control. 2018 Nov 08;11:73-79
pubmed: 30519088
Diabetes Care. 2012 Nov;35(11):2402-11
pubmed: 23093685
Gastroenterology. 2017 Jun;152(8):1809-1812.e3
pubmed: 28461196
JAMA Oncol. 2017 Apr 01;3(4):464-471
pubmed: 27978560
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):352-364
pubmed: 32086499
Clin Colorectal Cancer. 2017 Dec;16(4):293-299.e6
pubmed: 29033218
Lancet. 1974 Feb 9;1(7850):181-3
pubmed: 4129874
Cancer Epidemiol. 2016 Jun;42:181-5
pubmed: 27203465
Cancer. 2016 Sep 1;122(17):2663-70
pubmed: 27219715
Mediators Inflamm. 2017;2017:4803156
pubmed: 28522899
J Environ Pathol Toxicol Oncol. 2011;30(3):213-23
pubmed: 22126614
Ann Oncol. 2009 Jun;20(6):1113-20
pubmed: 19164459
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Mol Oncol. 2019 Feb;13(2):109-131
pubmed: 30520562
Rev Environ Health. 2017 Sep 26;32(3):253-266
pubmed: 28682789